NASDAQ:HYPD - US30234E2037 - Common Stock
The current stock price of HYPD is 6.1 USD. In the past month the price decreased by -35.79%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 43.05 | 658.10B | ||
JNJ | JOHNSON & JOHNSON | 17.84 | 429.67B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 14.52 | 250.34B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 17.94 | 246.98B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.13 | 242.06B | ||
MRK | MERCK & CO. INC. | 11.08 | 213.09B | ||
PFE | PFIZER INC | 7.42 | 142.93B | ||
SNY | SANOFI-ADR | 11.37 | 122.26B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 7 | 95.95B | ||
GSK | GSK PLC-SPON ADR | 8.83 | 79.91B | ||
ZTS | ZOETIS INC | 24.95 | 68.78B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.97 | 47.59B |
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2018-01-25. The company is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
HYPERION DEFI INC
295 Madison Ave Ste 2400
New York City NEW YORK US
Employees: 13
Phone: 18137669539
The current stock price of HYPD is 6.1 USD. The price decreased by -0.97% in the last trading session.
The exchange symbol of HYPERION DEFI INC is HYPD and it is listed on the Nasdaq exchange.
HYPD stock is listed on the Nasdaq exchange.
HYPERION DEFI INC (HYPD) has a market capitalization of 34.71M USD. This makes HYPD a Nano Cap stock.
HYPERION DEFI INC (HYPD) currently has 13 employees.
The Revenue of HYPERION DEFI INC (HYPD) is expected to grow by 400.98% in the next year. Check the estimates tab for more information on the HYPD EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HYPD does not pay a dividend.
HYPERION DEFI INC (HYPD) will report earnings on 2025-11-10, after the market close.
HYPERION DEFI INC (HYPD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-34.16).
The outstanding short interest for HYPERION DEFI INC (HYPD) is 6.93% of its float. Check the ownership tab for more information on the HYPD short interest.
ChartMill assigns a technical rating of 1 / 10 to HYPD.
ChartMill assigns a fundamental rating of 1 / 10 to HYPD. HYPD may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months HYPD reported a non-GAAP Earnings per Share(EPS) of -34.16. The EPS increased by 43.07% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -708.22% | ||
ROE | N/A | ||
Debt/Equity | N/A |
For the next year, analysts expect an EPS growth of 33.51% and a revenue growth 400.98% for HYPD